Figure 6

SP6616 effectively ameliorates hyperglycemia in type 2 diabetic model mice. Fasting serum glucose level was detected weekly in (a) HFD/STZ and (b) db/db mice with treatment of SP6616 (50 mg/kg/day) (n=8) (black circles, Vehicle group (V); black squares, SP6616 group (SP6616)). Plasma HbA1c level in (c) HFD/STZ and (d) db/db mice after treatment with SP6616 for 5 weeks was determined. OGTT was performed in (e) HFD/STZ and (f) db/db mice with SP6616 treatment (n=8). (g) AUC result of OGTT in e. (h) AUC result of OGTT in f. (i) Serum insulin concentration was determined during OGTT of (e) by AlphaLISA insulin kit. (j) Serum insulin concentration was determined during OGTT of f. All data were presented as means±S.E.M. (*P<0.05, **P<0.01, ***P<0.01)